PROTHERA BIOLOGICS, INC.
Providence, RI · CIK 0001659513 · Biotech · Private
Inter-alpha Inhibitor Proteins (IAIPs) therapeutic for perinatal brain injury neuroprotection
protherabiologics.com →- Grants
- $13M
- 14 awards
- Sector median: 1
- Raised
- $250K
- 2 Form D · Jan 2018
- 105 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 23
- 4 granted · 19 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201720192021202320252027
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic Role of Inter-alpha Inhibitors in Wound Healing | $224,688 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic Role of Inter-alpha Inhibitors in Wound Healing | $224,688 | |
| Private capital raised | Form D · SEC | $1 | |
| Federal grant | Department of Health and Human Services · Phase II · Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury | $984,466 | |
| Private capital raised | Form D · SEC | $250,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury | $941,149 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis | $166,522 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis | $862,493 | |
| Federal grant | Department of Health and Human Services · Phase II · Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury | $2,776,920 | |
| Federal grant | Department of Health and Human Services · Phase II · Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury | $2,776,920 | |
| Federal grant | Department of Health and Human Services · Phase I · Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis | $378,272 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis | $987,396 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis | $971,267 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis | $50,184 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis | $954,189 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1479 | General LED, Inc. | — | $941K |
| 1480 | Arch Biopartners Inc. | — | $631K |
| 1481 | Eyevance Pharmaceuticals | — | — |
| 1482 | PROTHERA BIOLOGICS, INC. | — | $250K |
| 1483 | Modulate Bio Inc. | — | $200K |
| 1484 | Aperta Biosciences, LLC | — | $175K |
| 1485 | Treovir, Inc. | — | $133K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Richard AndrewsDirector
- Douglas HixsonDirector
- Richard HoranDirector
- Pierre LaurinDirector
- Yow-Pin LimDirector · Executive Officer
- Denice SperoExecutive Officer
Patents
- Inter-alpha Inhibitor Proteins And Methods Of Use Thereofapplication
- Methods For Treating Pulmonary Disease Using Inter-alpha Inhibitor Proteinsgranted
- Inter-alpha Inhibitor Proteinsgranted
- Methods For Purifying Inter-alpha Inhibitor Proteinsapplication
- Inter-alpha Inhibitor Proteinsapplication
- Inter-alpha Inhibitor Proteins And Methods Of Use Thereofapplication
- Methods For Quantifying Inter-alpha Inhibitor Proteinsapplication
- Methods For Treating Pulmonary Disease Using Inter-alpha Inhibitor Proteinsapplication
- Preparation And Composition Of Inter-alpha Inhibitor Proteins From Bloodgranted
- Preparation And Composition Of Inter-alpha Inhibitor Proteins From Bloodgranted
- Methods For Isolating Blood Products From An Inter-alpha Inhibitor Protein-depleted Blood Product Materialapplication
- Methods For Isolating Blood Products From An Inter-alpha Inhibitor Protein-depleted Blood Product Materialapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.